U.S. License Holder:
Eli Lilly and Co.
Date of License:
TALTZ (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of adults with:
moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy;
active psoriatic arthritis.
Inter Partes Review ProceedingsPTAB Portal
IPR Case No(s):
U.S. Patent No.
10,011,654 (Antibodies Directed to IL-17A/IL-17F)
Eli Lilly & Co.
§ 102 Challenge
Claim Types Challenged Under § 102
Composition of Matter Formulation
§ 102 Challenge Instituted
Awaiting Institution Decision
§ 103 challenge
Challenges also lack of written description and enablement. Institution Decision Pending